Advanced BioMedical Technologies, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-03-13: Form 8-K; Period of report 2020-03-13; Description 8.01 Other Events; Details 8.01.
- 2020-03-09: Form 8-K; Period of report 2020-03-09; Description 8.01 Other Events; Details 8.01.
- 2018-04-26: Form 8-K; Period of report 2018-04-19; Description 8.01 Other Events; Details 8.01.
- 2017-04-28: Form 8-K; Period of report 2017-04-28; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-03-13 | 8-K | 2020-03-13 | 8.01 Other Events | 8.01 Advanced Biomedical Technologies, Inc. (the “Company”) is filing this report in compliance with the SEC’s exemptive order issued on March 4, 2020, providing conditional regulatory relief to public companies affected by the recent coronavirus disease 2019 (COVID-19) outbreak. | form8-k.htm |
| 2020-03-09 | 8-K | 2020-03-09 | 8.01 Other Events | 8.01 On March 9, 2020, Advanced Biomedical Technologies, Inc. (the “Company”) announced the appointment of Prof. | form8-k.htm |
| 2018-04-26 | 8-K | 2018-04-19 | 8.01 Other Events | 8.01 On April 19, 2018, Advanced Biomedical Technologies, Inc. (the “Company”) issued a press release announcing that it had received approval from the Chinese Food and Drug Administration (“CFDA”) for the polymer orthopaedic internal fixation screws (“PA Screws”) developed by the Company’s subsidiary Shenzhen Changhua Biomedical Engineering Company Limited. | form8-k.htm |
| 2017-04-28 | 8-K | 2017-04-28 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 On April 28, 2017, Advanced BioMedical Technologies, Inc. (the “Company”) entered into a debt conversion agreement (the “Debt Conversion Agreement”) with Titan Technology Development Ltd., a Hong Kong corporation (“TTD” and “LENDER”), pursuant to which the Company and TTD agreed to convert $100,000 of the accrued interest of the outstanding debt owed by the Company to TTD into shares of the Company’s Common Stock at a conversion price of $0.05 per share. 3.02 As disclosed under Item 1.01 of this Current Report on Form 8-K, on April 28, 2017 the Company issued 2,000,000 shares of its Common Stock to TTD in exchange for cancellation of $100,000 of accrued and unpaid interest on loans owed by the Company to TTD. 5.07 On April 28, 2017, holders of 70.32% of the Company’s common stock voted in favor of converting $100,000 of the accrued interest of the outstanding debt owed by the Company to TTD into shares of the Company’s Common Stock at a conversion price of $0.05 per share. | f8k20170428.htm |
| 2016-05-06 | 8-K | 2016-05-04 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 Advanced Biomedical Technologies Inc. (the “Company”) was notified that, effective April 30, 2016, AWC (CPA) Limited (“AWC”) has merged (the “Merger”) with Dominic K.F. Chan & Co (“DKFC”) and formed DCAW (CPA) Limited (“DCAW”), which is registered with the Public Company Accounting Oversight Board (PCAOB). | abmt-8k_050416.htm |
| 2015-11-16 | 8-K | 2015-11-16 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 Advanced BioMedical Technologies, Inc. (“we”, “our”, “us”, the “Company”) was notified in writing that, effective from November 16, 2015, Baker Tilly Hong Kong Limited (“BTHK”), resigned as the independent registered public accounting firm of the Company and with the approval of the Company’s Board of Directors, AWC (CPA) Limited (“AWC”) was then engaged as the Company’s independent registered public accounting firm. | f8kbthk.htm |
| 2015-11-16 | 8-K | 2015-11-13 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 On November 13, 2015, Advanced BioMedical Technologies, Inc. (the “Company”) entered into a debt conversion agreement (the “Debt Conversion Agreement”) with Titan Technology Development Ltd., a Hong Kong corporation (“TTD” and “LENDER”), pursuant to which the Company and TTD agreed to convert $500,000 of the accrued interest of the outstanding debt owed by the Company to TTD into shares of the Company’s Common Stock at a conversion price of $0.05 per share. 3.02 As disclosed under Item 1.01 of this Current Report on Form 8-K, on November 13, 2015 the Company issued 10,000,000 shares of its Common Stock to TTD in exchange for cancellation of $500,000 of accrued and unpaid interest on loans owed by the Company to TTD. 5.07 On November 13, 2015, holders of 65.43% of the Company’s common stock voted in favor of converting $500,000 of the accrued interest of the outstanding debt owed by the Company to TTD into shares of the Company’s Common Stock at a conversion price of $0.05 per share. | f8kdebt1113.htm |
| 2011-11-02 | 8-K | 2011-11-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 Effective October 31, 2011, Que Yong resigned from the Company’s board of directors for personal reasons. 8.01 Effective November 1, 2011, the Company formed a Scientific Advisory Board (SAB) to advise the Board of Directors in order to help the Company meet its goals. | abmt8k11111.htm |
| 2011-05-26 | 8-K | 2011-05-25 | 8.01 Other Events | 8.01 Effective May, 25, 2011, the Company formed a Board of Advisors to advise the Board of Directors in order to help the Company meet its goals. | abmt-8k_052511.htm |
| 2010-03-15 | 8-K | 2010-03-10 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 Advanced BioMedical Technologies, Inc. (“we”, “our”, “us”, the “Company”) was notified that, effective January 29, 2010, the US Audit Practice of Jimmy CH Cheung & Co, the Company’s independent registered public accounting firm (“JCHC”), merged with Baker Tilly Hong Kong Limited (“BTHK”). | abmt-8k_0315.htm |
| 2009-01-29 | 8-K/A | 2008-12-31 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On January 9, 2009, the Board of Directors, by unanimous consent rescinded the Board’s prior approval of a change in Registrant’s fiscal year from a fiscal year ending on October 31 to a fiscal year ending on December 31. | v138166_8ka.htm |
| 2009-01-06 | 8-K | 2008-12-31 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.06 Change in Shell Company Status; 8.01 Other Events | 1.01 On December 31, 2008, the Company entered into a share exchange agreement (“Share Exchange Agreement”) which is attached to this current report on Form 8-K as Exhibit 10.1, under which the Company issued 50,000 shares of its common stock, par value $0.00001, to Titan , a limited liability company organized under the laws of Hong Kong, and WANG Hui, an individual, (Titan and WANG Hui being the sole shareholders of Masterise) in exchange for 100% of Masterise Shares. 2.01 As described under Item 1.01, On December 31, 2008, the Company entered into a share exchange agreement (“Share Exchange Agreement”) which is attached to this current report on Form 8-K as Exhibit 10.1, under which the Company issued 50,000 shares of its common stock, par value $0.00001, to Titan, a limited liability company organized under the laws of Hong Kong, and WANG Hui, an individual, (Titan and WANG Hui being the sole shareholders of Masterise) in exchange for 100% of Masterise. 3.02 On December 31, 2008, the Company entered into a share exchange agreement (“Share Exchange Agreement”) which is attached to this current report on Form 8-K as Exhibit 10.1, under which the Company issued 50,000 shares of its common stock, par value $0.00001, to Titan, a limited liability company organized under the laws of Hong Kong, and WANG Hui, an individual, (Titan and WANG Hui being the sole shareholders of Masterise Holdings Ltd.) in exchange for 100% of the issued and outstanding shares of common stock of Masterise. 5.01 As described in the Item 1, On December 31, 2008, the Company entered into a share exchange agreement (“Share Exchange Agreement”) which is attached to this current report on Form 8-K as Exhibit 10.1, under which the Company issued 50,000 shares of its common stock, par value $0.00001, to Titan, a limited liability company organized under the laws of Hong Kong, and WANG Hui, an individual, (Titan and WANG Hui being the sole shareholders of Masterise) in exchange for 100% of the issued and outstanding shares of common stock of Masterise. 5.02 WANG Hui has been appointed as the Chief Executive Officer of Geostar Mineral Corporation. 5.03 On December 31, 2008, the Board of Directors, by unanimous consent, voted to change the name of the Company to Advanced BioMedical Technologies, Inc. Also on December 31, 2008, the Board of Directors approved a change in our fiscal year from a fiscal year ending on October 31 to a fiscal year ending on December 31. 5.06 Upon the acquisition of Masterise and its subsidiary Shenzhen Changhua, the Company ceased being a “shell company” as that term is defined in Rule 12b-2 under the Securities and Exchange Act of 1934 (the “Exchange Act”). 8.01 The Company determined on December 31, 2008 that it would be in the best interests of the Company to cause a 10:1 forward split of the Company’s common stock, par value $0.00001 per share (the “Forward Split”), whereby the total number of issued and outstanding shares of the Company’s common stock held by each shareholder will be converted automatically into the number of whole shares of common stock equal to the number of issued and outstanding shares of common stock held by such shareholder immediately prior to the Forward Split, multiplied by ten. | v136279_8k.htm |
| 2008-12-18 | 8-K | 2008-12-16 | 4.01 Changes in Registrant's Certifying Accountant | geos8kitem401.htm | |
| 2008-10-07 | 8-K | 2008-10-01 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | geos8kfinal1.htm | |
| 2008-09-11 | 8-K | 2008-09-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | gmc8k91008.htm |